Fig. 5From: Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysisEFS in IDH-mutant AML patients treated with IDH inhibitors. A 2-year EFS rate in newly diagnosed AML patients treated with IDH inhibitors; B 2-year EFS rate in newly diagnosed AML patients treated with IDH inhibitors in combination; C Median EFS in relapsed or refractory AML patients treated with IDH inhibitors alone. EFS event-free survival, AML acute myeloid leukemia, IDH isocitrate dehydrogenase genes, 95% CI 95% confidence intervalBack to article page